1
|
Sandu N, Schaller B. Postconditioning: a new or old option after ischemic stroke? Expert Rev Cardiovasc Ther 2014; 8:479-82. [DOI: 10.1586/erc.09.180] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
2
|
Spiriev T, Sandu N, Schaller B. Molecular imaging and tracking stem cells in neurosciences. Methods Mol Biol 2013; 1052:195-201. [PMID: 23640257 DOI: 10.1007/7651_2013_27] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Stem cell transplantation is a promising new therapeutic option in different neurological diseases. However, it is not yet possible to translate its potential from animal models to clinical application. One of the main problems of applying stem cell transplantation in clinical medium is the difficulty of detection, localization, and examination of the stem cells in vivo at both cellular and molecular levels. State-of-the-art molecular imaging techniques provide new and better means for noninvasive, repeated, and quantitative tracking of stem cell implant or transplant. From initial deposition to the survival, migration, and differentiation of the transplant/implanted stem cells, current molecular imaging methods allow monitoring of the infused cells in the same live recipient over time. The present review briefly summarizes and compares these molecular imaging methods for cell labeling and imaging in animal models as well as in clinical application and sheds light on consecutive new therapeutic options if appropriate.
Collapse
Affiliation(s)
- Toma Spiriev
- Department of Neurosurgery, Tokuda Hospital Sofia, Sofia, Bulgaria
| | | | | |
Collapse
|
3
|
Gehring K, Roukema JA, Sitskoorn MM. Review of recent studies on interventions for cognitive deficits in patients with cancer. Expert Rev Anticancer Ther 2012; 12:255-69. [PMID: 22316373 DOI: 10.1586/era.11.202] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Research has demonstrated that patients with cancer experience cognitive deficits, often due to aggressive anticancer treatments. In this article, we critically review the interventional studies that have been conducted to investigate beneficial effects on cognitive function in cancer patients. Pharmacological agents that have been studied include psychostimulants, such as methylphenidate and modafinil, erythropoietin, and hormonal (supplement) treatments for patients who receive hormonal suppression therapy. In addition, several cognitive rehabilitation programs have been evaluated in cancer patients. Recently, the approach of physical exercise to treat cognitive deficits has received great interest, and findings from novel studies are keenly anticipated. Although, in general, the studies reviewed were well designed, future studies may wish to include larger sample sizes and pay more attention to the accurate assessment of cognitive function.
Collapse
Affiliation(s)
- Karin Gehring
- Tilburg University, Department of Medical Psychology and Neuropsychology, Center of Research on Psychology in Somatic Diseases, Prisma Building, 5000 LE, Tilburg, The Netherlands.
| | | | | |
Collapse
|
4
|
Sandu N, Schaller B. Molecular imaging of stem cell therapy in brain tumors: a step towards personalized medicine. Arch Med Sci 2012; 8:601-5. [PMID: 23056068 PMCID: PMC3460495 DOI: 10.5114/aoms.2012.30282] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2010] [Revised: 11/24/2010] [Accepted: 12/14/2010] [Indexed: 11/17/2022] Open
Affiliation(s)
- Nora Sandu
- Department of Neurosurgery, University of Lausanne, Switzerland
| | | |
Collapse
|
5
|
Chang JY, Chiang MF, Lin SR, Lee MH, He H, Chou PY, Chen SJ, Chen YA, Yang LY, Lai FJ, Hsieh CC, Hsieh TH, Sheu HM, Sze CI, Chang NS. TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death. Cell Death Dis 2012; 3:e302. [PMID: 22534828 PMCID: PMC3358014 DOI: 10.1038/cddis.2012.36] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2011] [Revised: 02/10/2012] [Accepted: 02/14/2012] [Indexed: 12/22/2022]
Abstract
Self-aggregation of transforming growth factor β (TGF-β)1-induced antiapoptotic factor (TIAF1) is known in the nondemented human hippocampus, and the aggregating process may lead to generation of amyloid β (Aβ) for causing neurodegeneration. Here, we determined that overexpressed TIAF1 exhibits as aggregates together with Smad4 and Aβ in the cancer stroma and peritumor capsules of solid tumors. Also, TIAF1/Aβ aggregates are shown on the interface between brain neural cells and the metastatic cancer cell mass. TIAF1 is upregulated in developing tumors, but may disappear in established metastatic cancer cells. Growing neuroblastoma cells on the extracellular matrices from other cancer cell types induced production of aggregated TIAF1 and Aβ. In vitro induction of TIAF1 self-association upregulated the expression of tumor suppressors Smad4 and WW domain-containing oxidoreductase (WOX1 or WWOX), and WOX1 in turn increased the TIAF1 expression. TIAF1/Smad4 interaction further enhanced Aβ formation. TIAF1 is known to suppress SMAD-regulated promoter activation. Intriguingly, without p53, self-aggregating TIAF1 spontaneously activated the SMAD-regulated promoter. TIAF1 was essential for p53-, WOX1- and dominant-negative JNK1-induced cell death. TIAF1, p53 and WOX1 acted synergistically in suppressing anchorage-independent growth, blocking cell migration and causing apoptosis. Together, TIAF1 shows an aggregation-dependent control of tumor progression and metastasis, and regulation of cell death.
Collapse
Affiliation(s)
- J-Y Chang
- Institute of Molecular Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - M-F Chiang
- Department of Neurosurgery, Mackay Memorial Hospital, Graduate Institute of Injury Prevention and Control, Taipei Medical University, Taipei, Taiwan, ROC
| | - S-R Lin
- Institute of Molecular Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - M-H Lee
- Institute of Molecular Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - H He
- Institute of Molecular Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - P-Y Chou
- Institute of Molecular Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - S-J Chen
- Institute of Molecular Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - Y-A Chen
- Institute of Molecular Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - L-Y Yang
- Institute of Molecular Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - F-J Lai
- Department of Dermatology, Chi-Mei Medical Center, Tainan, Taiwan, ROC
| | - C-C Hsieh
- Department of Dermatology, Chi-Mei Medical Center, Tainan, Taiwan, ROC
| | - T-H Hsieh
- Department of Anatomy and Cell Biology, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - H-M Sheu
- Department of Dermatology, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - C-I Sze
- Department of Anatomy and Cell Biology, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
| | - N-S Chang
- Institute of Molecular Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
- Department of Neurosurgery, Mackay Memorial Hospital, Graduate Institute of Injury Prevention and Control, Taipei Medical University, Taipei, Taiwan, ROC
- Advanced Optoelectronic Technology Center, National Cheng Kung University College of Medicine, Tainan, Taiwan, ROC
- Center of Infectious Disease and Signal Research, National Cheng Kung University, Tainan, Taiwan, ROC
- Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA
| |
Collapse
|
6
|
Sandu N, Momen-Heravi F, Sadr-Eshkevari P, Schaller B. Molecular imaging for stem cell transplantation in neuroregenerative medicine. NEURODEGENER DIS 2011; 9:60-7. [PMID: 22042219 DOI: 10.1159/000330713] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2011] [Accepted: 06/03/2011] [Indexed: 12/12/2022] Open
Abstract
Stem cell transplantation is a promising new therapeutic option in different neurological diseases. However, it was not yet possible to translate its potential from animal models to clinical application. One of the main problems of applying stem cell transplantation in clinical medium is the difficulty of detection, localization, and examination of the stem cells in vivo at both cellular and molecular levels. State-of-the-art molecular imaging techniques provide new and better means for noninvasive, repeated, and quantitative tracking of stem cell implant or transplant. From initial deposition to the survival, migration, and differentiation of the transplant/implanted stem cells, current molecular imaging methods allow monitoring of the infused cells in the same live recipient over time. The present review briefly summarizes and compares these molecular imaging methods for cell labeling and imaging in animal models as well as in clinical application and sheds light on consecutive new therapeutic options if appropriate.
Collapse
Affiliation(s)
- Nora Sandu
- Department of Neurosurgery, University of Lausanne, Lausanne, Switzerland
| | | | | | | |
Collapse
|
7
|
Sandu N, Pöpperl G, Toubert ME, Spiriev T, Arasho B, Orabi M, Schaller B. Current molecular imaging of spinal tumors in clinical practice. Mol Med 2011; 17:308-16. [PMID: 21210073 PMCID: PMC3060992 DOI: 10.2119/molmed.2010.00218] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2010] [Accepted: 01/03/2011] [Indexed: 11/06/2022] Open
Abstract
Energy metabolism measurements in spinal cord tumors, as well as in osseous spinal tumors/metastasis in vivo, are rarely performed only with molecular imaging (MI) by positron emission tomography (PET). This imaging modality developed from a small number of basic clinical science investigations followed by subsequent work that influenced and enhanced the research of others. Apart from precise anatomical localization by coregistration of morphological imaging and quantification, the most intriguing advantage of this imaging is the opportunity to investigate the time course (dynamics) of disease-specific molecular events in the intact organism. Most importantly, MI represents one of the key technologies in translational molecular neuroscience research, helping to develop experimental protocols that may later be applied to human patients. PET may help monitor a patient at the vertebral level after surgery and during adjuvant treatment for recurrent or progressive disease. Common clinical indications for MI of primary or secondary CNS spinal tumors are: (i) tumor diagnosis, (ii) identification of the metabolically active tumor compartments (differentiation of viable tumor tissue from necrosis) and (iii) prediction of treatment response by measurement of tumor perfusion or ischemia. While spinal PET has been used under specific circumstances, a question remains as to whether the magnitude of biochemical alterations observed by MI in CNS tumors in general (specifically spinal tumors) can reveal any prognostic value with respect to survival. MI may be able to better identify early disease and to differentiate benign from malignant lesions than more traditional methods. Moreover, an adequate identification of treatment effectiveness may influence patient management. MI probes could be developed to image the function of targets without disturbing them or as treatment to modify the target's function. MI therefore closes the gap between in vitro and in vivo integrative biology of disease. At the spinal level, MI may help to detect progression or recurrence of metastatic disease after surgical treatment. In cases of nonsurgical treatments such as chemo-, hormone- or radiotherapy, it may better assess biological efficiency than conventional imaging modalities coupled with blood tumor markers. In fact, PET provides a unique possibility to correlate topography and specific metabolic activity, but it requires additional clinical and experimental experience and research to find new indications for primary or secondary spinal tumors.
Collapse
Affiliation(s)
- Nora Sandu
- Department of Neurological Surgery, Lariboisière Hospital, Universities of Paris, France
- Department of Neurological Surgery, University of Lausanne, Switzerland
| | | | | | - Toma Spiriev
- Department of Neurological Surgery, Lariboisière Hospital, Universities of Paris, France
- Department of Neurosurgery, Tokuda Hospital, Sofia, Bulgaria
| | - Belachew Arasho
- Department of Neurological Surgery, Lariboisière Hospital, Universities of Paris, France
- Department of Neurology, University of Addis Ababa, Ethiopia
| | - Mikael Orabi
- Department of Neurological Surgery, Lariboisière Hospital, Universities of Paris, France
| | - Bernhard Schaller
- Department of Neurological Surgery, Lariboisière Hospital, Universities of Paris, France
- Department of Neurology, University of Addis Ababa, Ethiopia
| |
Collapse
|
8
|
Sandu N, Schaller B. Stem cell transplantation in brain tumors: a new field for molecular imaging? Mol Med 2010; 16:433-7. [PMID: 20593112 DOI: 10.2119/molmed.2010.00035] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2010] [Accepted: 06/28/2010] [Indexed: 01/23/2023] Open
Abstract
Neural stem cells have been proposed as a new and promising treatment modality in various pathologies of the central nervous system, including malignant brain tumors. However, the underlying mechanism by which neural stem cells target tumor areas remains elusive. Monitoring of these cells is currently done by use of various modes of molecular imaging, such as optical imaging, magnetic resonance imaging and positron emission tomography, which is a novel technology for visualizing metabolism and signal transduction to gene expression. In this new context, the microenvironment of (malignant) brain tumors and the blood-brain barrier gains increased interest. The authors of this review give a unique overview of the current molecular-imaging techniques used in different therapeutic experimental brain tumor models in relation to neural stem cells. Such methods for molecular imaging of gene-engineered neural stem/progenitor cells are currently used to trace the location and temporal level of expression of therapeutic and endogenous genes in malignant brain tumors, closing the gap between in vitro and in vivo integrative biology of disease in neural stem cell transplantation.
Collapse
Affiliation(s)
- Nora Sandu
- Department of Neurosurgery, University of Lausanne, Lausanne, Switzerland
| | | |
Collapse
|
9
|
Sandu N, Cornelius J, Filis A, Arasho B, Perez-Pinzon M, Schaller B. Ischemic tolerance in stroke treatment. Expert Rev Cardiovasc Ther 2010; 7:1255-61. [PMID: 19814668 DOI: 10.1586/erc.09.90] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Although outcome after stroke treatment has significantly improved over the last 30 years, there has been no revolutionary breakthrough. Among different combined approaches, systemic thrombolysis in combination with neuroprotection became a favorite research target. Recent studies suggest that transient ischemic attacks may represent a clinical model of such ischemic tolerance; thus, a new focus on this research has emerged. In this review, we show the parallels between ischemia and neuroprotection and discuss the potential therapeutic options that may be opened by this new molecular knowledge.
Collapse
Affiliation(s)
- Nora Sandu
- Department of Neurosurgery, University of Lausanne, Lausanne, Switzerland
| | | | | | | | | | | |
Collapse
|
10
|
Schaller B, Cornelius JF, Sandu N. Molecular medicine successes in neuroscience. Mol Med 2008; 14:361-4. [PMID: 18496586 DOI: 10.2119/2008-00055.schaller] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2008] [Accepted: 05/07/2008] [Indexed: 11/06/2022] Open
Affiliation(s)
- Bernhard Schaller
- Department of Neurosurgery, University Hospital Lariboisière, Paris, France
| | | | | |
Collapse
|
11
|
Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJB. Interventions for cognitive deficits in adults with brain tumours. Lancet Neurol 2008; 7:548-60. [PMID: 18485318 DOI: 10.1016/s1474-4422(08)70111-x] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Increased life expectancy in patients with brain tumours has led to a greater risk of cognitive deficits, particularly during disease-free periods. Here, we review the empirical studies that have been done to treat or to prevent cognitive impairment in patients with brain tumours. Both pharmacological interventions and cognitive rehabilitation programmes have been used. Although both types of study have reported some successes, these are often difficult to interpret owing to limitations in the methods used. Most of the studies reviewed did not use a randomised group design to control for possible confounding factors such as placebo and practice effects. Investigations of newer, targeted therapies have reported delays in cognitive deterioration, but these need to be confirmed in future studies. Neuroprotection represents another potentially promising, novel approach to prevention of cognitive impairment in this vulnerable population of patients. Finally, we describe studies in patients with cancers outside the CNS, to highlight further possibilities for the prevention and treatment of cognitive deficits.
Collapse
Affiliation(s)
- Karin Gehring
- Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, Netherlands
| | | | | | | |
Collapse
|
12
|
Abstract
Dementia represents a heterogeneous term that has evolved to describe the behavioral syndromes associated with a variety of clinical and neuropathological changes during continuing degenerative disease of the brain. As such, there lacks a clear consensus regarding the neuropsychological and other constituent characteristics associated with various cerebrovascular changes in this disease process. But increasing this knowledge has given more insights into memory deterioration in patients suffering from Alzheimer's disease and other subtypes of dementia. The author reviews current knowledge of the physiological coupling between cerebral blood flow and metabolism in the light of state-of-the-art-imaging methods and its changes in dementia with special reference to Alzheimer's disease. Different imaging techniques are discussed with respect to their visualizing effect of biochemical, cellular, and/or structural changes in dementia. The pathophysiology of dementia in advanced age is becoming increasingly understood by revealing the underlying basis of neuropsychological changes with current imaging techniques, genetic and pathological features, which suggests that alterations of (neuro) vascular regulatory mechanisms may lead to brain dysfunction and disease. The current view is that cerebrovascular deregulation is seen as a contributor to cerebrovascular pathologies, such as stroke, but also to neurodegenerative conditions, such as Alzheimer's disease. The better understanding of these (patho) physiological mechanisms may open an approach to new interventional strategies in dementia to enhance neurovascular repair and to protect neurovascular coupling.
Collapse
|
13
|
Schaller BJ, Modo M, Buchfelder M. Molecular Imaging of Brain Tumors: A Bridge Between Clinical and Molecular Medicine? Mol Imaging Biol 2007; 9:60-71. [PMID: 17203238 DOI: 10.1007/s11307-006-0069-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
As the research on cellular changes has shed invaluable light on the pathophysiology and biochemistry of brain tumors, clinical and experimental use of molecular imaging methods is expanding and allows quantitative assessment. The term molecular imaging is defined as the in vivo characterization and measurement of biologic processes at the cellular and molecular level. Molecular imaging sets forth to probe the molecular abnormalities that are the basis of disease rather than to visualize the end effects of these molecular alterations and, therefore, provides different additional biochemical or molecular information about primary brain tumors compared to histological methods "classical" neuroradiological diagnostic studies. Common clinical indications for molecular imaging contain primary brain tumor diagnosis and identification of the metabolically most active brain tumor reactions (differentiation of viable tumor tissue from necrosis), prediction of treatment response by measurement of tumor perfusion, or ischemia. The interesting key question remains not only whether the magnitude of biochemical alterations demonstrated by molecular imaging reveals prognostic value with respect to survival, but also whether it identifies early disease and differentiates benign from malignant lesions. Moreover, an early identification of treatment success or failure by molecular imaging could significantly influence patient management by providing more objective decision criteria for evaluation of specific therapeutic strategies. Specially, as molecular imaging represents a novel technology for visualizing metabolism and signal transduction to gene expression, reporter gene assays are used to trace the location and temporal level of expression of therapeutic and endogenous genes. Molecular imaging probes and drugs are being developed to image the function of targets without disturbing them and in mass amounts to modify the target's function as a drug. Molecular imaging helps to close the gap between in vitro and in vivo integrative biology of disease.
Collapse
Affiliation(s)
- B J Schaller
- Neuroscience Imaging, Department of Neurological Surgery, University of Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany.
| | | | | |
Collapse
|